Betty Wu has more than 20 years of experience in the molecular diagnostic industry. Dr. Wu joined Talis as VP, Assay Development in December 2021. Before joining Talis, Dr. Wu spent 8 years leading assay development for NeuMoDx Molecular, a molecular diagnostics company that was acquired by Qiagen in 2020. Prior to that, Dr. Wu served as a consultant for Life Magnetic Inc. Earlier in her career, Dr. Wu was a senior scientist at Handylab, a molecular diagnostics company. Over the course of her career, she holds eight patents, and has authored many peer-reviewed research papers. Dr. Wu received a BS in Medicine from Beijing University of Chinese Medicine, and an MS and Ph.D. in Biology from Wayne State University in Detroit, Michigan.